CD19 and congenital rubella syndrome: The study's primary outcomes included the incidence of CRS, ICANS, and the number of patients achieving an early complete response (CR) and overall response (OR) rates at one-month post-infusion of anti-CD19 shRNA-engineered CAR-T cells.